Orexo AB (publ) (ORX.ST)
SEK 14.0
(-1.13%)
SEK 14.0
(-1.13%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22 Million SEK | 38.46% |
| 2022 | -73.9 Million SEK | 47.56% |
| 2021 | -141.3 Million SEK | -941.07% |
| 2020 | 16.8 Million SEK | -94.17% |
| 2019 | 288.4 Million SEK | 122.7% |
| 2018 | 110.3 Million SEK | 171.49% |
| 2017 | 57.6 Million SEK | -37.89% |
| 2016 | 80.8 Million SEK | 187.02% |
| 2015 | -88.25 Million SEK | -361.15% |
| 2014 | -12.22 Million SEK | 78.33% |
| 2013 | -92.37 Million SEK | -52.27% |
| 2012 | -57.95 Million SEK | 85.02% |
| 2011 | -108.03 Million SEK | -381.97% |
| 2010 | -46.55 Million SEK | 14.75% |
| 2009 | -94.21 Million SEK | 8.73% |
| 2008 | -92.76 Million SEK | -156.3% |
| 2007 | -166.93 Million SEK | 60.67% |
| 2006 | -29.52 Million SEK | 54.33% |
| 2005 | -40.34 Million SEK | 377.59% |
| 2004 | 15.48 Million SEK | -41.75% |
| 2003 | 26.57 Million SEK | 24.55% |
| 2002 | 21.34 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.6 Million SEK | -20.5% |
| 2024 Q2 | -200 Thousand SEK | -68.55% |
| 2024 Q3 | -700 Thousand SEK | -114.0% |
| 2023 Q3 | -9.4 Million SEK | -270.91% |
| 2023 Q4 | 20 Million SEK | 312.77% |
| 2023 FY | - SEK | 38.46% |
| 2023 Q2 | 5.5 Million SEK | 113.38% |
| 2023 Q1 | -41.1 Million SEK | -251.28% |
| 2022 Q1 | 2.8 Million SEK | 109.76% |
| 2022 Q2 | -32.5 Million SEK | -1260.71% |
| 2022 Q3 | -32.4 Million SEK | 0.31% |
| 2022 Q4 | -11.7 Million SEK | 63.89% |
| 2022 FY | - SEK | 47.56% |
| 2021 FY | - SEK | -941.07% |
| 2021 Q1 | -23.9 Million SEK | -2290.0% |
| 2021 Q2 | -41.2 Million SEK | -72.38% |
| 2021 Q4 | -28.7 Million SEK | 39.32% |
| 2021 Q3 | -47.3 Million SEK | -14.81% |
| 2020 Q3 | -20.9 Million SEK | -450.0% |
| 2020 Q1 | 42.7 Million SEK | -58.1% |
| 2020 FY | - SEK | -94.17% |
| 2020 Q2 | -3.8 Million SEK | -108.9% |
| 2020 Q4 | -1 Million SEK | 95.22% |
| 2019 Q2 | 60.4 Million SEK | 403.33% |
| 2019 Q3 | 114.1 Million SEK | 88.91% |
| 2019 Q4 | 101.9 Million SEK | -10.69% |
| 2019 FY | - SEK | 122.7% |
| 2019 Q1 | 12 Million SEK | -78.49% |
| 2018 Q3 | 39.8 Million SEK | -21.34% |
| 2018 FY | - SEK | 171.49% |
| 2018 Q2 | 50.6 Million SEK | 404.82% |
| 2018 Q4 | 55.8 Million SEK | 40.2% |
| 2018 Q1 | -16.6 Million SEK | -147.16% |
| 2017 Q3 | 46.5 Million SEK | 222.92% |
| 2017 Q2 | 14.4 Million SEK | 180.9% |
| 2017 Q1 | -17.8 Million SEK | -146.23% |
| 2017 FY | - SEK | -37.89% |
| 2017 Q4 | 35.2 Million SEK | -24.3% |
| 2016 FY | - SEK | 187.02% |
| 2016 Q3 | 50.9 Million SEK | 197.66% |
| 2016 Q2 | 17.1 Million SEK | 188.14% |
| 2016 Q1 | -19.4 Million SEK | -178.09% |
| 2016 Q4 | 38.5 Million SEK | -24.36% |
| 2015 FY | - SEK | -361.15% |
| 2015 Q1 | -5.1 Million SEK | -108.98% |
| 2015 Q2 | -74.2 Million SEK | -1354.9% |
| 2015 Q3 | -33.9 Million SEK | 54.31% |
| 2015 Q4 | 24.84 Million SEK | 173.28% |
| 2014 Q2 | -35.5 Million SEK | -159.12% |
| 2014 Q4 | 56.76 Million SEK | 314.2% |
| 2014 FY | - SEK | 78.33% |
| 2014 Q3 | -26.5 Million SEK | 25.35% |
| 2014 Q1 | -13.7 Million SEK | 51.41% |
| 2013 Q1 | 31.6 Million SEK | 279.46% |
| 2013 Q2 | -67.6 Million SEK | -313.92% |
| 2013 Q4 | -28.19 Million SEK | -17.98% |
| 2013 Q3 | -23.9 Million SEK | 64.64% |
| 2013 FY | - SEK | -52.27% |
| 2012 FY | - SEK | 85.02% |
| 2012 Q4 | -17.6 Million SEK | 36.43% |
| 2012 Q2 | -12.8 Million SEK | -4.92% |
| 2012 Q3 | -27.7 Million SEK | -116.41% |
| 2012 Q1 | -12.2 Million SEK | 95.41% |
| 2011 FY | - SEK | -381.97% |
| 2011 Q4 | -265.57 Million SEK | -332.96% |
| 2011 Q3 | -61.34 Million SEK | -164.77% |
| 2011 Q2 | -23.16 Million SEK | 35.77% |
| 2011 Q1 | -36.07 Million SEK | -1016.9% |
| 2010 Q3 | -25.61 Million SEK | 19.91% |
| 2010 Q1 | -26.66 Million SEK | 49.77% |
| 2010 FY | - SEK | 14.75% |
| 2010 Q2 | -31.97 Million SEK | -19.91% |
| 2010 Q4 | 3.93 Million SEK | 115.36% |
| 2009 FY | - SEK | 8.73% |
| 2009 Q1 | 26.22 Million SEK | 474.44% |
| 2009 Q2 | -55.23 Million SEK | -310.6% |
| 2009 Q3 | -5.8 Million SEK | 89.48% |
| 2009 Q4 | -53.09 Million SEK | -813.93% |
| 2008 Q3 | -684 Thousand SEK | 0.0% |
| 2008 Q4 | -7 Million SEK | -923.98% |
| 2008 FY | - SEK | -156.3% |
| 2007 FY | - SEK | 60.67% |
| 2006 FY | - SEK | 54.33% |
| 2005 FY | - SEK | 377.59% |
| 2004 FY | - SEK | -41.75% |
| 2003 FY | - SEK | 24.55% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -60.69% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 41.903% |
| BioGaia AB (publ) | 466.19 Million SEK | 104.719% |
| Enzymatica AB (publ) | -41.12 Million SEK | 46.501% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 48.9% |
| Gabather AB (publ) | 37 Thousand SEK | 59559.459% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -48.951% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 18.396% |
| Nanexa AB (publ) | -70.79 Million SEK | 68.923% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -78.282% |
| ODI Pharma AB | 1.36 Million SEK | 1708.936% |
| Probi AB (publ) | 115.61 Million SEK | 119.029% |
| Swedencare AB (publ) | 484 Million SEK | 104.545% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 100.304% |
| Toleranzia AB | -7.39 Million SEK | -197.378% |
| Vivesto AB | -89.75 Million SEK | 75.49% |